Release date: 2016-02-29 Research co-leader Professor Andrew Biankin and colleagues at the University of Glasgow's College of Cancer Sciences have discovered four “key subtypes†of cancer, each with its own unique clinical characteristics and differentiated survival outcomes, according to the week. A statement published in a statement. The researchers published the paper in Nature and named the subtype as: - squamous subtype - Pancreatic progenitor cell subtype - immunogenic subtype - Abnormal differentiation of endocrine exocrine glands, or ADEX subtypes. Currently, pancreatic cancer is one of the worst prognosis groups in patients. According to the British Cancer Research Report, about 5% of patients diagnosed with pancreatic cancer have a five-year or longer survival period, and only 1% of patients survive more than 10 years after diagnosis. The Hersheyberg Pancreatic Cancer Study points out that the treatment plan for pancreatic cancer is “limited†and that less than one in five patients can be surgically removed. Apple co-founder and former CEO Steve Jobs died of the disease in 2011. Peter Bailey, the first author of the study, said that the current treatment of pancreatic cancer "is like a disease with a wooden chop in a closed eye." The University of Glasgow announced that the researchers hope the findings will "help to identify the right targeted treatment for each disease subtype." The study used data from the Australian Pancreatic Cancer Genome Project and the Queensland Medical Genomics Center. A key finding of the study was the identification of immunogenic subtypes. It has been found that this subtype may "provide a subtype that is likely to respond to cancer immunotherapy," the university noted. “The four subtypes identified have been reclassified for this disease, providing a new insight base for patients' personalized treatment options and a new platform for researching new treatments,†Director of the Wolfson Wall Cancer Research Center. Biankin, chairman of the University Surgery Lecture. Bailey added that the work he and his colleagues have been doing is always looking for a clinical landscape that changes pancreatic cancer and other cancers, "by providing a very thorough analysis of the molecular pathology of specific cancers", which will help Lead to more precise treatments. Biankin's personalized medical research is sponsored by the UK Pancreatic Cancer Future Leadership Fund. "The results of this study are extremely exciting for any patient suffering from pancreatic cancer, because it means that patients can be given the right treatment at the right time in the future," said Lynn Reynolds, head of charity research. I said. “If we can more accurately predict the most effective treatment for each patient, we can ensure that patients have the best chance of achieving the longest possible survival,†Reynolds continues. Source: Noble Organic Garlic Granules,Organic Granulated Garlic,Garlic Powder To Minced Garlic,Bulk Granulated Garlic Powder shandong changrong international trade co.,ltd. , https://www.changronggarliccn.com
British researchers have made a “breakthrough reclassification†of pancreatic cancer, providing new treatment opportunities for this deadly disease.